home / stock / hnsbf / hnsbf quote
Last: | $2.93 |
---|---|
Change Percent: | 0.0% |
Open: | $2.93 |
Close: | $2.93 |
High: | $2.93 |
Low: | $2.93 |
Volume: | 150 |
Last Trade Date Time: | 03/14/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.93 | $2.93 | $2.93 | $2.93 | $2.93 | 150 | 03-14-2024 |
$3.255 | $0 | $3.255 | $0 | $0 | 4,000 | 03-11-2024 |
$3.255 | $3.255 | $3.255 | $3.255 | $3.255 | 900 | 02-15-2024 |
$3.3 | $3.22 | $3.3 | $3.3 | $3.22 | 200 | 01-29-2024 |
$2.65 | $2.65 | $2.65 | $2.65 | $2.65 | 500 | 01-02-2024 |
$2.257 | $0 | $2.257 | $0 | $0 | 8,000 | 12-27-2023 |
$2.257 | $2.257 | $2.257 | $2.257 | $2.257 | 700 | 12-19-2023 |
$3 | $0 | $3 | $0 | $0 | 50 | 10-10-2023 |
$3 | $3 | $3 | $3 | $3 | 100 | 10-03-2023 |
$3.93 | $3.93 | $3.93 | $3.93 | $3.93 | 130 | 09-05-2023 |
$3.93 | $3.93 | $3.93 | $3.93 | $3.93 | 2,000 | 08-29-2023 |
$4.755 | $4.755 | $4.755 | $4.755 | $4.755 | 1,000 | 07-31-2023 |
$5.295 | $0 | $5.295 | $0 | $0 | 40 | 07-27-2023 |
$5.295 | $0 | $5.295 | $0 | $0 | 2 | 07-18-2023 |
$5.295 | $5.295 | $5.295 | $5.295 | $5.295 | 1,000 | 05-11-2023 |
$5.2 | $0 | $5.2 | $0 | $0 | 4,000 | 05-05-2023 |
$5.2 | $0 | $5.2 | $0 | $0 | 8 | 03-09-2023 |
$5.2 | $0 | $5.2 | $0 | $0 | 30 | 03-08-2023 |
$5.2 | $5.2 | $5.2 | $5.2 | $5.2 | 1,120 | 02-02-2023 |
$5.92 | $5.92 | $5.92 | $5.92 | $5.92 | 240 | 02-01-2023 |
News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
OTCMKTS Market:
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...
The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients PR Newswire Idefirix ® becomes the first and only product recommended by SMC...